• Samsung Biologics showcases new innovative development platforms - S-AfuCHOTM and S-OptiChargeTM - at BioProcess International 2024
  • New technology platforms to proactively address evolving industry trends and enable high-quality development
INCHEON, South Korea, Sept. 25, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), launched today a series of proprietary development platforms as part of continued efforts to ensure high-quality development and provide client-tailored services.

S-AfuCHOTM, introduced at BioProcess International 2024, is a cell line platform that can generate afucosylated antibodies that exhibit enhanced antibody-dependent cellular cytotoxity (ADCC) activity for increased therapeutic efficacy. The platform removes the core fucose from Fc N-glycans through knockout of the host (FUT8) gene to achieve higher ADCC activity while retaining desired titers, stability, and product quality (Figure 1).

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here